In Vitro and in Vivo Activities of a New Cephalosporin, FR264205, Against Pseudomonas Aeruginosa

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Dec 6

PMID 17145788

Citations 41

Authors

Shinobu Takeda

Toru Nakai

Yoshimi Wakai

Fumiaki Ikeda

Kazuo Hatano

Affiliations

Soon will be listed here.

Abstract

FR264205 is a novel parenteral 3'-aminopyrazolium cephalosporin. This study evaluated the in vitro and in vivo activities of FR264205 against Pseudomonas aeruginosa. The MIC of FR264205 at which 90% of 193 clinical isolates of P. aeruginosa were inhibited was 1 microg/ml, 8- to 16-fold lower than those of ceftazidime (CAZ), imipenem (IPM), and ciprofloxacin (CIP). FR264205 also exhibited this level of activity against CAZ-, IPM-, and CIP-resistant P. aeruginosa. The reduction in the susceptibility of FR264205 by AmpC beta-lactamase was lower than that of CAZ, indicating a relatively high stability of FR264205 against AmpC beta-lactamase, the main resistance mechanism for cephalosporins. Neither expression of efflux pumps nor deficiency of OprD decreased the activity of FR264205. No spontaneous resistance mutants were selected in the presence of FR264205, and the reduction in susceptibility to FR264205 was lower than that to CAZ, IPM, and CIP after serial passage, suggesting that FR264205 has a low propensity for selecting resistance. In murine pulmonary, urinary tract, and burn wound models of infection caused by P. aeruginosa, the efficacy of FR264205 was superior or comparable to those of CAZ and IPM. These results indicate that FR264205 should have good potential as an antibacterial agent for P. aeruginosa.

Citing Articles

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.

Kostoulias X, Fu Y, Morris F, Yu C, Qu Y, Chang C J Antimicrob Chemother. 2024; 80(2):372-380.

PMID: 39657684 PMC: 11787898. DOI: 10.1093/jac/dkae413.

Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis.

Gupta C, Shin-Jung Lee S, Sahu M, Mukherjee S, Wu K Infection. 2024; 52(6):2183-2193.

PMID: 39180705 DOI: 10.1007/s15010-024-02371-1.

Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility.

Ling C, Sud K, Patel R, Peterson G, Wanandy T, Yeoh S J Nephrol. 2023; 36(7):1841-1859.

PMID: 37548827 PMC: 10543841. DOI: 10.1007/s40620-023-01716-7.

New antibiotics for Gram-negative pneumonia.

Bassetti M, Magne F, Giacobbe D, Bini L, Vena A Eur Respir Rev. 2022; 31(166).

PMID: 36543346 PMC: 9879346. DOI: 10.1183/16000617.0119-2022.

Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of from five Latin American countries.

Mojica M, De la Cadena E, Rios R, Garcia-Betancur J, Diaz L, Reyes J Front Microbiol. 2022; 13:1035609.

PMID: 36353456 PMC: 9638110. DOI: 10.3389/fmicb.2022.1035609.

References

Gordon K, Jones R . Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance.... Diagn Microbiol Infect Dis. 2003; 45(4):295-301. DOI: 10.1016/s0732-8893(02)00467-4. View

Santucci S, Gobara S, Santos C, Fontana C, Levin A . Infections in a burn intensive care unit: experience of seven years. J Hosp Infect. 2002; 53(1):6-13. DOI: 10.1053/jhin.2002.1340. View

Jones R, Deshpande L, Bell J, Turnidge J, Kohno S, Hirakata Y . Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn Microbiol Infect Dis. 2004; 49(4):289-94. DOI: 10.1016/j.diagmicrobio.2004.04.007. View

Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B . Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros. 2004; 3(3):159-63. DOI: 10.1016/j.jcf.2004.03.010. View

Levesque R, Medeiros A, Jacoby G . Molecular cloning and DNA homology of plasmid-mediated beta-lactamase genes. Mol Gen Genet. 1987; 206(2):252-8. DOI: 10.1007/BF00333581. View

Jacoby G, Sutton L . Properties of plasmids responsible for production of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35(1):164-9. PMC: 244959. DOI: 10.1128/AAC.35.1.164. View

Bush K, Jacoby G, Medeiros A . A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995; 39(6):1211-33. PMC: 162717. DOI: 10.1128/AAC.39.6.1211. View

Masuda N, Gotoh N, Ohya S, Nishino T . Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40(4):909-13. PMC: 163229. DOI: 10.1128/AAC.40.4.909. View

Kohler T, Henze U, Gotoh N, Curty L, Pechere J . Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol. 1997; 23(2):345-54. DOI: 10.1046/j.1365-2958.1997.2281594.x. View

10.

Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T . Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998; 42(8):1938-43. PMC: 105713. DOI: 10.1128/AAC.42.8.1938. View

11.

. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8):470-85. DOI: 10.1016/S0196655304005425. View

12.

Juan C, Gutierrez O, Oliver A, Ayestaran J, Borrell N, Perez J . Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect. 2005; 11(11):887-92. DOI: 10.1111/j.1469-0691.2005.01251.x. View

13.

Livermore D . Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001; 47(3):247-50. DOI: 10.1093/jac/47.3.247. View

14.

De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J . Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother. 2002; 46(9):3031-4. PMC: 127436. DOI: 10.1128/AAC.46.9.3031-3034.2002. View

15.

Geyik M, Aldemir M, Hosoglu S, Tacyildiz H . Epidemiology of burn unit infections in children. Am J Infect Control. 2003; 31(6):342-6. DOI: 10.1016/s0196-6553(02)48226-0. View